The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at ...

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care ...

It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...

Dermavant Sciences Ltd. to Organon & Co. for $1.2 billion. The massive amount comprises an up-front $175 million payment, along with a potential $75 million regulatory milestone and up to $950 million ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.